Format

Send to

Choose Destination
Oncotarget. 2018 Jun 22;9(48):28989-29006. doi: 10.18632/oncotarget.25615. eCollection 2018 Jun 22.

The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target.

Author information

1
Center for Molecular Medicine and Immunology, Belleville, NJ, USA.
2
IBC Pharmaceuticals, Inc., Morris Plains, NJ, USA.
3
Immunomedics, Inc., Morris Plains, NJ, USA.

Abstract

TROP-2 is a glycoprotein first described as a surface marker of trophoblast cells, but subsequently shown to be increased in many solid cancers, with lower expression in certain normal tissues. It regulates cancer growth, invasion and spread by several signaling pathways, and has a role in stem cell biology and other diseases. This review summarizes TROP-2's properties, especially in cancer, and particularly its role as a target for antibody-drug conjugates (ADC) or immunotherapy. When the irinotecan metabolite, SN-38, is conjugated to a humanized anti-TROP-2 antibody (sacituzumab govitecan), it shows potent broad anticancer activity in human cancer xenografts and in patients with advanced triple-negative breast, non-small cell and small-cell lung, as well as urothelial cancers.

KEYWORDS:

TACSTD2; TROP-2; antibody-drug conjugates; immunotherapy; sacituzumab govitecan

Conflict of interest statement

CONFLICTS OF INTEREST Drs. Goldenberg and Sharkey own Immunomedics stock or stock options, and Dr. Goldenberg holds patented inventions. Dr. Goldenberg is the founder of the Center for Molecular Medicine and Immunology (CMMI), and also the retired founder of Immunomedics, Inc., and IBC Pharmaceuticals, Inc.

Publication type

Publication type

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center